Death, relapse, and new malignancy
| . | BMT . | PBSC . | UCB . | . |
|---|---|---|---|---|
| . | (N = 102) . | (N = 458) . | (N = 517) . | P . |
| Death, % | .50 | |||
| Day 0 to 100 | 15 (14.7) | 73 (15.9) | 96 (18.6) | |
| Days 101 to 365 | 23 (22.5) | 101 (22.1) | 97 (18.8) | |
| Years 1 to 5 | 15 (14.7) | 83 (18.1) | 83 (16.1) | |
| Alive at 5 y | 49 (48.0) | 201 (43.9) | 241 (46.6) | |
| Relapsed or progression, % | .22 | |||
| Day 0 to 100 | 11 (10.8) | 73 (15.9) | 61 (11.8) | |
| Days 101 to 365 | 14 (13.7) | 49 (10.7) | 62 (12.0) | |
| Years 1 to 5 | 3 (2.9) | 34 (7.4) | 35 (6.8) | |
| No relapse | 74 (72.5) | 302 (65.9) | 359 (69.4) | |
| New malignancy, % | .35 | |||
| Day 0 to 100 | 1 (1.0) | 4 (0.9) | 6 (1.2) | |
| Days 101 to 365 | 2 (2.0) | 10 (2.2) | 14 (2.7) | |
| Years 1 to 5 | 4 (3.9) | 34 (7.4) | 19 (3.7) | |
| No malignancy before death or by 5 y | 95 (93.1) | 410 (89.5) | 478 (92.5) | |
| Number of alive subjects during each period, % | ||||
| Day 0 to 100 | 102 | 458 | 517 | |
| Days 101 to 365 | 87 | 385 | 421 | |
| Years 1 to 5 | 52 | 265 | 295 | |
| Relapse/progression-free subjects during each period | ||||
| Day 0 to 100 | 102 | 458 | 517 | |
| Days 101 to 365 | 79 | 326 | 372 | |
| Years 1 to 5 | 42 | 218 | 239 |
| . | BMT . | PBSC . | UCB . | . |
|---|---|---|---|---|
| . | (N = 102) . | (N = 458) . | (N = 517) . | P . |
| Death, % | .50 | |||
| Day 0 to 100 | 15 (14.7) | 73 (15.9) | 96 (18.6) | |
| Days 101 to 365 | 23 (22.5) | 101 (22.1) | 97 (18.8) | |
| Years 1 to 5 | 15 (14.7) | 83 (18.1) | 83 (16.1) | |
| Alive at 5 y | 49 (48.0) | 201 (43.9) | 241 (46.6) | |
| Relapsed or progression, % | .22 | |||
| Day 0 to 100 | 11 (10.8) | 73 (15.9) | 61 (11.8) | |
| Days 101 to 365 | 14 (13.7) | 49 (10.7) | 62 (12.0) | |
| Years 1 to 5 | 3 (2.9) | 34 (7.4) | 35 (6.8) | |
| No relapse | 74 (72.5) | 302 (65.9) | 359 (69.4) | |
| New malignancy, % | .35 | |||
| Day 0 to 100 | 1 (1.0) | 4 (0.9) | 6 (1.2) | |
| Days 101 to 365 | 2 (2.0) | 10 (2.2) | 14 (2.7) | |
| Years 1 to 5 | 4 (3.9) | 34 (7.4) | 19 (3.7) | |
| No malignancy before death or by 5 y | 95 (93.1) | 410 (89.5) | 478 (92.5) | |
| Number of alive subjects during each period, % | ||||
| Day 0 to 100 | 102 | 458 | 517 | |
| Days 101 to 365 | 87 | 385 | 421 | |
| Years 1 to 5 | 52 | 265 | 295 | |
| Relapse/progression-free subjects during each period | ||||
| Day 0 to 100 | 102 | 458 | 517 | |
| Days 101 to 365 | 79 | 326 | 372 | |
| Years 1 to 5 | 42 | 218 | 239 |